Robert Joseph Cobuzzi Jr. - May 2, 2022 Form 4 Insider Report for Diffusion Pharmaceuticals Inc. (DFFN)

Signature
/s/ William R. Elder, attorney-in-fact for the Reporting Person
Stock symbol
DFFN
Transactions as of
May 2, 2022
Transactions value $
$0
Form type
4
Date filed
5/3/2022, 06:24 PM
Previous filing
Apr 19, 2022
Next filing
Aug 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DFFN Common Stock Options Exercise +327 +41.29% 1.12K May 2, 2022 Direct F1
transaction DFFN Common Sock Disposed to Issuer -121 -10.81% 998 May 2, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DFFN Restricted Stock Unit Options Exercise $0 -327 -25% $0.00 981 May 2, 2022 Common Stock 327 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 2, 2022 (the "Vesting Date"), in connection with the vesting of previously awarded restricted stock units ("RSUs"), each RSU representing a contingent right to receive one share of the Issuer's common stock (a "Share"), the Reporting Person became entitled to receive, in accordance with Section 8.7 of the Issuer's 2015 Equity Incentive Plan (as amended, the "Plan") and the terms of the underlying award agreement, (i) 206 Shares and (ii) $842.09 in cash, representing the Fair Market Value (as defined in the 2015 Equity Plan) of the remaining portion of the award vested on the Vesting Date, based on the closing sale price of one Share reported by the NASDAQ Stock Market on such date of $6.96. The remainder of the award will continue to vest in tri-monthly installments, subject to the Reporting Person's continued service with the Issuer.